Update on the use of long-acting growth hormone in children
- PMID: 38747211
- DOI: 10.1097/MOP.0000000000001362
Update on the use of long-acting growth hormone in children
Abstract
Purpose of review: After extensive research and many years of waiting, long-acting growth hormone (LAGH) formulations have finally become a reality in clinical practice and emerge as a potential solution to address the challenges of daily injections of recombinant human GH (rhGH). In this review, we present a brief history of the development of LAGH and provide a critical analysis of the existing literature on the five LAGH available and approved to date for treatment in children.
Recent findings: In clinical trials, LAGH therapy has shown noninferiority compared with daily rhGH therapy in promoting linear growth in children with GH deficiency, with similar rates of adverse events.
Summary: In the real world, many questions still need to be answered, such as whether a specific group of patients will benefit most from the weekly injection, whether compliance will be better compared with daily rhGH, whether long-term efficacy, monitoring and safety profile will be the same for the different LAGH compounds, and whether the cost-effectiveness will justify their use in different settings.
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Similar articles
-
Five-year safety and growth response of long-acting PEGylated recombinant human growth hormone in children with growth hormone deficiency-data from CGLS database.Eur J Pediatr. 2025 Jun 21;184(7):434. doi: 10.1007/s00431-025-06268-5. Eur J Pediatr. 2025. PMID: 40542826 Free PMC article.
-
Real-Life Growth Hormone Treatment Patterns in Children from China: A Report from Two Databases.Adv Ther. 2025 Jul;42(7):3562-3575. doi: 10.1007/s12325-025-03204-9. Epub 2025 May 29. Adv Ther. 2025. PMID: 40439954 Free PMC article.
-
Efficacy and Safety of Somapacitan Relative to Somatrogon and Lonapegsomatropin in Pediatric Growth Hormone Deficiency: Systematic Literature Review and Network Meta-analysis.Adv Ther. 2024 Nov;41(11):4098-4124. doi: 10.1007/s12325-024-02966-y. Epub 2024 Sep 11. Adv Ther. 2024. PMID: 39261416 Free PMC article.
-
Efficacy, safety, quality of life, adherence and cost-effectiveness of long-acting growth hormone replacement therapy compared to daily growth hormone in children with growth hormone deficiency: A systematic review and meta-analysis.Pharmacol Res. 2023 Jul;193:106805. doi: 10.1016/j.phrs.2023.106805. Epub 2023 May 24. Pharmacol Res. 2023. PMID: 37236413
-
First 100 patients receiving long-acting growth hormone therapy: real-world evaluation from INSIGHTS-GHT registry.Orphanet J Rare Dis. 2025 Jul 23;20(1):372. doi: 10.1186/s13023-025-03898-8. Orphanet J Rare Dis. 2025. PMID: 40702497 Free PMC article.
References
-
- Rogol AD, Reiter EO. Growth and growth hormone through the ages: art and science. Horm Res Paediatr 2022; 95:515–528.
-
- Ranke MB, Wit JM. Growth hormone - past, present and future. Nat Rev Endocrinol 2018; 14:285–300.
-
- Lindholm J. Growth hormone: historical notes. Pituitary 2006; 9:5–10.
-
- Boguszewski CL, Boguszewski MCDS, de Herder WW. The science behind the relations among cancer, height, growth patterns, and growth hormone axis. Endocr Relat Cancer 2023; 30:e220400.
-
- Savage MO. The changing face of paediatric human growth hormone therapy. Endocrines 2022; 3:419–427.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials